Impetis’ pipeline of assets includes innovative potential treatments for difficult-to-treat therapeutic indications. Our programs are in preclinical development for auto-immune and inflammatory diseases as well as for immuno-oncology thus, providing hope for treatment of refractive and resistant cancers.

Impetis was founded in 2017 and is built around high value therapeutic candidates discovered by the highly talented and experienced scientific team at Advinus Therapeutics. Impetis was spun out as an independent Drug Discovery company focused on developing IP based on NCEs for critical therapy areas.